SIP
CAPR icon

Stoneridge Investment Partners’s Capricor Therapeutics CAPR Stock Holding History

Stoneridge Investment Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,397
Closed -$255K – 153
2026
Q1 		$255K Sell
8,397
-60
-0.7% -$1.6K 0.18% 91
2025
Q4 		$244K Buy
+8,457
New +$110K 0.17% 93
2025
Q2 		– Sell
-15,853
Closed -$150K – 131
2025
Q1 		$150K Buy
+15,853
New +$220K 0.13% 86

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Stoneridge Investment Partners's CAPR Position: Q2 2026 in Review

Stoneridge Investment Partners sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 8,397 shares — an estimated $255K sold.

Stoneridge Investment Partners first reported a position in CAPR in Q1 2025 and held it in 3 quarters. The position peaked at $255K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Stoneridge Investment Partners reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stoneridge Investment Partners sold 8,397 Capricor Therapeutics shares in Q2 2026, an estimated $255K.
  • Stoneridge Investment Partners first reported a position in Capricor Therapeutics in Q1 2025 and held it in 3 quarters.
  • Stoneridge Investment Partners's Capricor Therapeutics position peaked at $255K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.